Chemical activators of ZFP51 can engage various cellular signaling cascades to induce its activation. Forskolin serves as a direct activator of adenylate cyclase, catalyzing the conversion of ATP to cAMP. Elevated cAMP levels can activate protein kinase A (PKA), which is known to phosphorylate a spectrum of cellular proteins, including ZFP51. This cascade ensures that ZFP51 is functionally activated via phosphorylation. Similarly, IBMX, by inhibiting phosphodiesterases that degrade cAMP, effectively raises cAMP concentrations, which indirectly promotes PKA activation and subsequent phosphorylation of ZFP51. In parallel, Phorbol 12-myristate 13-acetate (PMA) operates through the protein kinase C (PKC) pathway, which phosphorylates a range of targets, and can also be implicated in the activation of ZFP51. This activation through PKC is further accentuated by Okadaic Acid, which, by inhibiting protein phosphatases PP1 and PP2A, prevents the dephosphorylation of proteins, indirectly contributing to the maintenance of ZFP51 in an activated state.
Complementing these mechanisms, Anisomycin activates stress-activated MAP kinase pathways, culminating in the phosphorylation and activation of various proteins, which can include the activation of ZFP51. Sodium Orthovanadate also plays a role by inhibiting protein tyrosine phosphatases, potentially leading to an increased state of phosphorylation within the cell that could encompass ZFP51 activation. Calyculin A's inhibition of protein phosphatases similarly elevates the phosphorylation status within the cell, which may include ZFP51. The cAMP pathway is again targeted by Zaprinast and Rolipram, which inhibit PDE5 and PDE4, respectively, resulting in increased cAMP levels that activate PKA and may lead to ZFP51 phosphorylation and activation. Finally, Dibutyryl-cAMP, a synthetic analog of cAMP, directly activates PKA, leading to phosphorylation of downstream proteins, including ZFP51, thus promoting its activation. These chemicals, through their distinct but often converging pathways, ensure the functional activation of ZFP51 by facilitating its phosphorylation state.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
IBMX | 28822-58-4 | sc-201188 sc-201188B sc-201188A | 200 mg 500 mg 1 g | $260.00 $350.00 $500.00 | 34 | |
Inhibits phosphodiesterases, which degrade cAMP, leading to increased levels of cAMP in the cell. This can enhance PKA activity, which may phosphorylate and activate ZFP51. | ||||||
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
Activates protein kinase C (PKC), which can phosphorylate and activate a range of substrates, potentially including ZFP51. | ||||||
Okadaic Acid | 78111-17-8 | sc-3513 sc-3513A sc-3513B | 25 µg 100 µg 1 mg | $291.00 $530.00 $1800.00 | 78 | |
Inhibits protein phosphatases PP1 and PP2A, leading to increased phosphorylation levels within the cell. This could maintain ZFP51 in a phosphorylated and active state. | ||||||
Anisomycin | 22862-76-6 | sc-3524 sc-3524A | 5 mg 50 mg | $99.00 $259.00 | 36 | |
Stimulates the stress-activated MAP kinase pathways, which can lead to the phosphorylation of various proteins. While not directly activating ZFP51, the activation of these pathways can lead to downstream phosphorylation and activation of ZFP51. | ||||||
Sodium Orthovanadate | 13721-39-6 | sc-3540 sc-3540B sc-3540A | 5 g 10 g 50 g | $49.00 $57.00 $187.00 | 142 | |
Inhibits protein tyrosine phosphatases, which may result in prolonged tyrosine phosphorylation of proteins. This can lead to the activation of downstream signaling molecules, potentially including ZFP51. | ||||||
Calyculin A | 101932-71-2 | sc-24000 sc-24000A | 10 µg 100 µg | $163.00 $800.00 | 59 | |
Inhibits certain protein phosphatases, leading to increased phosphorylation of proteins within the cell. This inhibitor may indirectly lead to the activation of ZFP51 through phosphorylation. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
Known to inhibit certain protein kinases indirectly, potentially leading to alterations in phosphorylation patterns that could activate ZFP51. | ||||||
Zaprinast (M&B 22948) | 37762-06-4 | sc-201206 sc-201206A | 25 mg 100 mg | $105.00 $250.00 | 8 | |
Inhibits phosphodiesterase 5 (PDE5), leading to increased cAMP levels, which could enhance PKA activity, potentially resulting in the activation of ZFP51 through phosphorylation. | ||||||
Rolipram | 61413-54-5 | sc-3563 sc-3563A | 5 mg 50 mg | $77.00 $216.00 | 18 | |
Inhibits phosphodiesterase 4 (PDE4), leading to elevated cAMP levels in the cell, which could lead to the activation of PKA and subsequent phosphorylation and activation of ZFP51. | ||||||
Dibutyryl-cAMP | 16980-89-5 | sc-201567 sc-201567A sc-201567B sc-201567C | 20 mg 100 mg 500 mg 10 g | $47.00 $136.00 $492.00 $4552.00 | 74 | |
A cAMP analog that directly activates PKA, leading to phosphorylation of downstream proteins, potentially including ZFP51 for its activation. | ||||||